Review Evaluates Dietary Supplements for Parkinson's Disease

No Supplement Proven to Slow Parkinson’s, Though Some Show Promise

A review published in the Journal of Parkinson's Disease assessed the potential of dietary supplements to modify the progression of Parkinson's disease. The authors examined human clinical trials, focusing on clinical outcomes and biomarkers as proxy measures. While some supplements such as omega-3 fatty acids, nicotinamide riboside, and biotics show promise, evidence remains mixed and no supplement has been proven to halt disease progression.

Key Findings

Some trials showed reduced inflammation and improved antioxidant defenses. However, results varied significantly across studies.

High doses improved MDS-UPDRS motor scores in some trials. Lower doses showed no benefit.

Multi-strain probiotics reduced inflammation and symptom severity in some studies, though the evidence is heterogeneous.

Vitamin D improved Hoehn and Yahr staging in one trial but did not improve total UPDRS scores. Vitamin E alone showed no major benefits; it was later tested in combination with omega-3.

Large trials for creatine and coenzyme Q10 failed to show disease modification. A small pilot trial for curcumin showed no significant improvement.

Conclusion

The authors conclude that no dietary supplement has definitive evidence to slow Parkinson's disease progression. They recommend larger, longer studies with precise biomarkers and suggest investigating combined approaches with lifestyle interventions. Critically, supplements should not replace standard medical care.